Related Experiment Video
Updated: May 19, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
PON1 (Paraoxonase 1) Q192R Gene Polymorphism in North Macedonian Population with Confirmed Coronary Artery Disease
K Krsteva Jakimovska1, M Vavlukis1,2, A Eftimov3
1Faculty of Medicine, Ss. Cyril and Methodius University in Skopje.
Aim:
This study aims to examine the association between the prevalence of Q192R polymorphism of PON1 gene and the occurrence of atherosclerosis and coronary artery disease in patients in Republic of North Macedonia.
Method:
This cross-sectional study includes subjects undergoing percutaneous coronary angiography with or without stenting due to monitoring of stable angina or induced ischemia, divided into two groups. Q192R polymorphism and its genotypic variants were analysed. The Polymerase Chain Reaction technique was used as a method for determining the single nucleotide polymorphism.
Results:
A total of 165 subjects (106 belonging to the coronary artery disease (CAD) group and 59 to non-CAD group were evaluated in terms of their biochemical parameters and genetic variants. Results of the PON1 SNP Q192R groups (QQ, QR and RR) association related to CAD and non-CAD groups, resulted in a non-significant association (p=0.0632, OR=0.511, CI: 0.25-0.595, χ2=3.4508, df=1). In further analyses, to obtain a more precise association, we analysed the association between SNP Q192R groups and stenting patients (control vs. stenting group). Further analysis confirmed the association of QQ vs. QR and control vs. stenting (p=0.0418, OR=0.461, CI: 0.216-0.589, χ2=4.1432, df=1).
Conclusion:
Results support the concept that genetic variants may contribute to an increased risk of CAD, emphasizing the importance of combined biochemical and genetic testing for better stratification of cardiovascular risk and early confirmation of the predisposition to develop serious cardiovascular disease. Further studies with a larger sample size are needed before Q192R gene polymorphism can be considered as a genetic risk factor for CAD.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
